1. An integrated in-silico approach for drug target identification in human pathogen Shigella dysenteriae.
- Author
-
Qureshi H, Basheer A, Sajjad W, Faheem M, and Babar Jamal S
- Subjects
- Humans, Genome, Bacterial, Bacterial Proteins genetics, Bacterial Proteins metabolism, Computational Biology methods, Shigella dysenteriae drug effects, Shigella dysenteriae genetics, Shigella dysenteriae pathogenicity, Anti-Bacterial Agents pharmacology, Molecular Docking Simulation, Computer Simulation, Dysentery, Bacillary microbiology, Dysentery, Bacillary drug therapy
- Abstract
Shigella dysenteriae, is a Gram-negative bacterium that emerged as the second most significant cause of bacillary dysentery. Antibiotic treatment is vital in lowering Shigella infection rates, yet the growing global resistance to broad-spectrum antibiotics poses a significant challenge. The persistent multidrug resistance of S. dysenteriae complicates its management and control. Hence, there is an urgent requirement to discover novel therapeutic targets and potent medications to prevent and treat this disease. Therefore, the integration of bioinformatics methods such as subtractive and comparative analysis provides a pathway to compute the pan-genome of S. dysenteriae. In our study, we analysed a dataset comprising 27 whole genomes. The S. dysenteriae strain SD197 was used as the reference for determining the core genome. Initially, our focus was directed towards the identification of the proteome of the core genome. Moreover, several filters were applied to the core genome, including assessments for non-host homology, protein essentiality, and virulence, in order to prioritize potential drug targets. Among these targets were Integration host factor subunit alpha and Tyrosine recombinase XerC. Furthermore, four drug-like compounds showing potential inhibitory effects against both target proteins were identified. Subsequently, molecular docking analysis was conducted involving these targets and the compounds. This initial study provides the list of novel targets against S. dysenteriae. Conclusively, future in vitro investigations could validate our in-silico findings and uncover potential therapeutic drugs for combating bacillary dysentery infection., Competing Interests: I have read the journal’s policy and the authors of this manuscript have no competing interests, (Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.)
- Published
- 2024
- Full Text
- View/download PDF